'On consolidated basis
Quarter ended September 2025 compared with Quarter ended September 2024.
Net sales (including other operating income) of Zydus Lifesciences has increased 16.92% to Rs 6123.2 crore. Sales of pharmaceuticals segment has gone up 15.31% to Rs 5,474.30 crore (accounting for 89.40% of total sales). Sales of Consumer Products segment has gone up 32.56% to Rs 648.90 crore (accounting for 10.60% of total sales).
Profit before interest, tax and other unallocable items (PBIT) has jumped 35.46% to Rs 1,721.60 crore. PBIT of pharmaceuticals segment rose 38.56% to Rs 1,738.80 crore (accounting for 101.00% of total PBIT). PBIT of Consumer Products reported loss of Rs 17.20 crore compared to profit of Rs 16.00 crore.
PBIT margin of pharmaceuticals segment rose from 26.43% to 31.76%. PBIT margin of Consumer Products segment fell from 3.27% to 2.65%. Ove...
Pleaselogin & subscribe to view the full report.
More Reports
|
|